Latest Antivirals Stories
NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free
GIA announces the release of a comprehensive global report on Growth Factors (Blood and Tissue) markets.
NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the
ResolveHerpes is Designed to Boost the Body's Immune System and Allow it to Clear Out the Herpes Viruses HSV-1 and HSV-2 LOS ANGELES, June 11, 2014 /PRNewswire-iReach/ -- Resolve Herpes,
EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No.
LONDON, June 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
polyDNA’s May 2014 survey revealed that 14% of elderly respondents wanted to know if a common virus could cause inflammatory bowel disease.
Ultimate Herpes Protocol reviews have been flooding the Internet and have caught the attention of health writer Laura O'Connor prompting her to review the program that claims to quickly, naturally,
ROCKLAND, Mass., May 28, 2014 /PRNewswire/ -- EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, Germany, announced today that Rebif(®) (interferon beta-1a) data will be presented at the 2014
-- Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) -- Health Canada grants AbbVie's request for Priority Review MONTREAL,
- Forsooth! indeed! originally a parenthetical phrase used in repeating the words of another with more or less contempt or disdain.